This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
Morning! Today, we discuss Madrigal’s impressive launch of its MASH drug Rezdiffra, see psychedelics player Compass Pathways shed 30% of its staff, and more.
Some drug launches go really well
From STAT’s Adam Feuerstein: Add Madrigal Pharmaceuticals to that list. Yesterday the company reported $62 million in third-quarter sales of Rezdiffra, its treatment for the serious liver disease known as MASH. Sales topped Street expectations by a wide margin, with the company more than tripling the number of patients on the drug from the end of the June quarter.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
